Until now, ST2 satisfies all criteria to represent a valid therapeutic and prognostic marker in patients with HF; additional studies are needed to identify if sST2 could also be a potential therapeutical target in this clinical condition. This evidence concerns the gene IL1RL1 and hydrops fetalis.